Advanced search
Publication Cover
Scandinavian Journal of Rheumatology Volume 35, 2006 - Issue 2
Submit an article Journal homepage
177
Views
67
CrossRef citations to date
0
Altmetric
Original

Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long‐term infliximab therapy

S. Rantapää Dahlqvist Departments of Public Health and Clinical Medicine, RheumatologyCorrespondence[email protected]
,
S. Engstrand Departments of Public Health and Clinical Medicine, Rheumatology
,
E. Berglin Departments of Public Health and Clinical Medicine, Rheumatology
&
O Johnson Cardiology, University Hospital, Umeå, Sweden
Pages 107-111 | Received 23 May 2005, Accepted 04 Nov 2005, Published online: 25 Aug 2009

Citations (67)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

George A Karpouzas, Viet L Bui, Nicoletta Ronda, Ivana Hollan & Sarah R Ormseth. (2021) Biologics and atherosclerotic cardiovascular risk in rheumatoid arthritis: a review of evidence and mechanistic insights. Expert Review of Clinical Immunology 17:4, pages 355-374.
Read now
Matteo Nicola Dario Di Minno, Pasquale Ambrosino, Rosario Peluso, Alessandro Di Minno, Roberta Lupoli & Francesco Dentali. (2014) Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-α blockers: A meta-analysis of prospective studies. Annals of Medicine 46:2, pages 73-83.
Read now
Sylvain Mathieu, Marion Couderc, Baptiste Glace, Bruno Pereira, Anne Tournadre, Jean-Jacques Dubost & Martin Soubrier. (2013) Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis. Biologics: Targets and Therapy 7, pages 259-264.
Read now
Alice B. Gottlieb, Chun Chao & Frank Dann. (2008) Psoriasis comorbidities. Journal of Dermatological Treatment 19:1, pages 5-21.
Read now
Michael T Nurmohamed. (2007) Atherogenic lipid profiles and its management in patients with rheumatoid arthritis. Vascular Health and Risk Management 3:6, pages 845-852.
Read now
A. Rosenvinge, R. Krogh‐Madsen, B. Baslund & B. K. Pedersen. (2007) Insulin resistance in patients with rheumatoid arthritis: effect of anti‐TNFα therapy. Scandinavian Journal of Rheumatology 36:2, pages 91-96.
Read now

Articles from other publishers (61)

Guadalupe Mendoza-Vázquez, Francisco Espinoza-Gómez, Alberto Daniel Rocha-Muñoz, Jorge I. Gamez-Nava, Laura Gonzalez-Lopez, Mario Salazar-Paramo, Carlos Riebeling-Navarro, Javier Alejandro Aceves-Aceves, Sandra Guzmán-Silahua & Arnulfo Hernán Nava-Zavala. (2022) Correlation between percentage of fat mass and level of disease activity in rheumatoid arthritis. SAGE Open Medicine 10, pages 205031212210858.
Crossref
Yonghong Luo, Xiaolei Ren, Shuwei Weng, Chunhui Yan, Qiaoxia Mao & Daoquan Peng. (2021) Improvements in High-Density Lipoprotein Quantity and Quality Contribute to the Cardiovascular Benefits by Anti-tumor Necrosis Factor Therapies in Rheumatoid Arthritis: A Systemic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine 8.
Crossref
John Nowicki & Gregory T. Yasuda. 2020. Textbook of Natural Medicine. Textbook of Natural Medicine 1767 1776.e2 .
HyunSoo Oh, JiSuk Park, YoungSub Yoon & WhaSook Seo. (2019) Comparisons of the Incidence and Critical Risk Factors of Metabolic Syndrome in Patients With a Rheumatic Disease or Gout. Orthopaedic Nursing 38:3, pages 201-208.
Crossref
Michael Nurmohamed, Ernest Choy, Sadiq Lula, Blerina Kola, Ryan DeMasi & Paola Accossato. (2018) The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review. Drug Safety 41:5, pages 473-488.
Crossref
Fatima Iqbal, Wendy S Baker, Madiha I Khan, Shwetha Thukuntla, Kevin H McKinney, Nicola Abate & Demidmaa Tuvdendorj. (2017) Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism. British Journal of Pharmacology 174:22, pages 3986-4006.
Crossref
C. Bonanad, E. González-Parra, R. Rivera, J.M. Carrascosa, E. Daudén, A. Olveira & R. Botella-Estrada. (2017) Clinical, Diagnostic, and Therapeutic Implications in Psoriasis Associated With Cardiovascular Disease. Actas Dermo-Sifiliográficas (English Edition) 108:9, pages 800-808.
Crossref
C. Bonanad, E. González-Parra, R. Rivera, J.M. Carrascosa, E. Daudén, A. Olveira & R. Botella-Estrada. (2017) Implicaciones clínicas, diagnósticas y terapéuticas de la psoriasis y enfermedad cardiovascular. Actas Dermo-Sifiliográficas 108:9, pages 800-808.
Crossref
Jingyang Li, Zhenhua Wen, Anlie Cai, Feng Tian, Liang Zhang, Xiaowen Luo, Li Deng, Jingyun He, Yicheng Yang & Wendong Chen. (2017) Real-world cost–effectiveness of infliximab for moderate-to-severe rheumatoid arthritis in a medium-sized city of China. Journal of Comparative Effectiveness Research 6:3, pages 205-218.
Crossref
Michelle S. M. A. Damen, Rabia Agca, Suzanne Holewijn, Jacqueline de Graaf, Jéssica C. Dos Santos, Piet L. van Riel, Jaap Fransen, Marieke J. H. Coenen, Mike T. Nurmohamed, Mihai G. Netea, Charles A. Dinarello, Leo A. B. Joosten, Bas Heinhuis & Calin D. Popa. (2017) IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid arthritis. Scientific Reports 7:1.
Crossref
Christina Charles-Schoeman, Xiaoyan Wang, Yuen Yin Lee, Ani Shahbazian, Iris Navarro-Millán, Shuo Yang, Lang Chen, Stacey S. Cofield, Larry W. Moreland, James O'Dell, Joan M. Bathon, Harold Paulus, S. Louis BridgesJr.Jr. & Jeffrey R. Curtis. (2016) Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis & Rheumatology 68:3, pages 577-586.
Crossref
Francesco Ursini, Emilio Russo, Marta Letizia Hribal, Daniele Mauro, Francesca Savarino, Caterina Bruno, Cesare Tripolino, Mariangela Rubino, Saverio Naty & Rosa Daniela Grembiale. (2015) Abatacept Improves Whole-Body Insulin Sensitivity in Rheumatoid Arthritis. Medicine 94:21, pages e888.
Crossref
Anna Filipowicz-Sosnowska, Piotr Głuszko & Robert Rupiński. (2014) Lipid profiles in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs. Rheumatology 52:2, pages 120-128.
Crossref
Bruce W Kirkham, Mary Chester Wasko, Elizabeth C Hsia, Roy M Fleischmann, Mark C Genovese, Eric L Matteson, Hongjuan Liu & Mahboob U Rahman. (2014) Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation. Annals of the Rheumatic Diseases 73:1, pages 161-169.
Crossref
Jeremy Hugh, Abby S. Van Voorhees, Rajiv I. Nijhawan, Jerry Bagel, Mark Lebwohl, Andrew Blauvelt, Sylvia Hsu & Jeffrey M. Weinberg. (2014) From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. Journal of the American Academy of Dermatology 70:1, pages 168-177.
Crossref
Andreas P. Diamantopoulos, Alf I. Larsen & Roald Omdal. (2013) Is it safe to use TNF-α blockers for systemic inflammatory disease in patients with heart failure? Importance of dosage and receptor specificity. International Journal of Cardiology 167:5, pages 1719-1723.
Crossref
Medha Barbhaiya & Daniel H. Solomon. (2013) Rheumatoid arthritis and cardiovascular disease. Current Opinion in Rheumatology 25:3, pages 317-324.
Crossref
K. P. Liao & D. H. Solomon. (2012) Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology 52:1, pages 45-52.
Crossref
Gregory T. Yasuda, Peter B. Bongiorno & Michael T. Murray. 2013. Textbook of Natural Medicine. Textbook of Natural Medicine 1769 1784 .
Bruce E. Strober, Jennifer Clay Cather, David Cohen, Jeffrey J. Crowley, Kenneth B. Gordon, Alice B. Gottlieb, Arthur F. Kavanaugh, Neil J. Korman, Gerald G. Krueger, Craig L. Leonardi, Sergio Schwartzman, Jeffrey M. Sobell, Gary E. Solomon & Melodie Young. (2012) A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatology and Therapy 2:1.
Crossref
Robert P Baughman, Keith C Meyer, Ian Nathanson, Luis Angel, Sangeeta M Bhorade, Kevin M Chan, Daniel Culver, Christopher G Harrod, Mary S Hayney, Kristen B Highland, Andrew H Limper, Herbert Patrick, Charlie Strange & Timothy Whelan. (2012) Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients. Chest 142:5, pages e1S-e111S.
Crossref
Jeffrey R. Curtis, Ani John & Onur Baser. (2012) Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti–tumor necrosis factor therapy. Arthritis Care & Research 64:9, pages 1282-1291.
Crossref
ANDRONIKI BILI, STEPHANIE J. MORRIS, JENNIFER A. SARTORIUS, H. LES KIRCHNER, JANA L. ANTOHE, SORINA DANCEA & MARY CHESTER WASKO. (2012) Tumor Necrosis Factor-α Inhibitor Use Is Not Associated with Lipid Changes in Rheumatoid Arthritis. The Journal of Rheumatology 39:5, pages 946-948.
Crossref
Javier Rueda-Gotor, Miguel A González-Gay & Ricardo Blanco. (2012) Tocilizumab for the treatment of rheumatoid arthritis. Clinical Practice 9:3, pages 255-268.
Crossref
C.I. Daïen & P. Fesler. (2012) La polyarthrite rhumatoïde : une maladie cardiovasculaire ?. Annales de Cardiologie et d'Angéiologie 61:2, pages 111-117.
Crossref
Hidetoshi TAKAHASHI & Hajime IIZUKA. (2012) Psoriasis and metabolic syndrome. The Journal of Dermatology 39:3, pages 212-218.
Crossref
Calin D. Popa, Elke Arts, Jaap Fransen & Piet L. C. M. van Riel. (2012) Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals. Mediators of Inflammation 2012, pages 1-9.
Crossref
Lotta Ljung, Julia F. Simard, Lennart Jacobsson, Solbritt Rantapää-Dahlqvist & Johan Askling. (2012) Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis & Rheumatism 64:1, pages 42-52.
Crossref
Louise E. Full & Claudia Monaco. (2011) Targeting Inflammation as a Therapeutic Strategy in Accelerated Atherosclerosis in Rheumatoid Arthritis. Cardiovascular Therapeutics 29:4, pages 231-242.
Crossref
Ronald F. van Vollenhoven. (2011) Unresolved issues in biologic therapy for rheumatoid arthritis. Nature Reviews Rheumatology 7:4, pages 205-215.
Crossref
Javier Rueda, Miguel A González-Gay & Ricardo Blanco. (2011) Tocilizumab for rheumatoid arthritis: results of the Phase III clinical trial program. Clinical Investigation 1:2, pages 345-354.
Crossref
Michael H Schiff, Joel M Kremer, Angelika Jahreis, Emma Vernon, John D Isaacs & Ronald F van Vollenhoven. (2011) Integrated safety in tocilizumab clinical trials. Arthritis Research & Therapy 13:5, pages R141.
Crossref
Adeline Ruyssen-Witrand, Bruno Fautrel, Alain Saraux, Xavier Le Loët & Thao Pham. (2011) Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: A systematic literature review. Joint Bone Spine 78:1, pages 23-30.
Crossref
Adeline Ruyssen-Witrand, Bruno Fautrel, Alain Saraux, Xavier Le Loët & Thao Pham. (2010) Risque cardiovasculaire associé à la corticothérapie à faible dose dans la polyarthrite rhumatoïde : revue de la littérature. Revue du Rhumatisme 77:6, pages 542-549.
Crossref
Inga-Lill Engvall, Birgitta Tengstrand, Kerstin Brismar & Ingiäld Hafström. (2010) Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Research & Therapy 12:5.
Crossref
I.H. Tarner, U. Müller-Ladner & C. Hamm. (2010) Biologika und kardiovaskuläres RisikoBiologics and cardiovascular risk. Zeitschrift für Rheumatologie 69:8, pages 702-711.
Crossref
Eduardo Nicolas Pollono, Maria A. Lopez-Olivo, Juan Antonio Martinez Lopez & Maria E. Suarez-Almazor. (2010) A systematic review of the effect of TNF-α antagonists on lipid profiles in patients with rheumatoid arthritis. Clinical Rheumatology 29:9, pages 947-955.
Crossref
Smriti K. RaychaudhuriSidhartha ChatterjeeCaroline NguyenManpreet KaurIshwarlal JialalSiba P. Raychaudhuri. (2010) Increased Prevalence of the Metabolic Syndrome in Patients with Psoriatic Arthritis. Metabolic Syndrome and Related Disorders 8:4, pages 331-334.
Crossref
Gino A. Vena, Michelangelo Vestita & Nicoletta Cassano. (2010) Can early treatment with biologicals modify the natural history of comorbidities?. Dermatologic Therapy 23:2, pages 181-193.
Crossref
Manfredi Rizzo, Giatgen A Spinas, Mustafa Cesur, Zeynep Ozbalkan, Giovam Battista Rini & Kaspar Berneis. (2009) Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis. Atherosclerosis 207:2, pages 502-506.
Crossref
Raquel Cuchacovich & Luis R. Espinoza. (2009) Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients?. Clinical Rheumatology 28:10, pages 1217-1220.
Crossref
Erika Parmentier-Decrucq, Alain Duhamel, Olivier Ernst, Catherine Fermont, Alexandre Louvet, Gwenola Vernier-Massouille, Antoine Cortot, Jean-Frédéric Colombel, Pierre Desreumaux & Laurent Peyrin-Biroulet. (2009) Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohnʼs disease. Inflammatory Bowel Diseases 15:10, pages 1476-1484.
Crossref
Xiuping Chen, Keli Xun, Lidian Chen & Yitao Wang. (2009) TNF‐ α , a potent lipid metabolism regulator . Cell Biochemistry and Function 27:7, pages 407-416.
Crossref
Bruce Strober, Emily Berger, Jennifer Cather, David Cohen, Jeffrey J. Crowley, Kenneth B. Gordon, Alice Gottlieb, Elizabeth J. Horn, Arthur F. Kavanaugh, Neal J. Korman, Gerald G. Krueger, Craig L. Leonardi, Alan Menter, Sergio Schwartzman, Jeffrey M. Sobell & Melodie Young. (2009) A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach. Journal of the American Academy of Dermatology 61:1, pages S1-S46.
Crossref
Ricardo Blanco Alonso & Mario Agudo Bilbao. (2009) La inhibición de la interleucina-6, una nueva opción terapéutica en la artritis reumatoide. Reumatología Clínica 5:3, pages 121-127.
Crossref
Mariann Harangi, Peter Szodoray & György Paragh. (2009) Atherosclerosis: a complex interplay of inflammatory processes. Clinical Lipidology 4:2, pages 167-187.
Crossref
Jennifer Channual, Jashin J. Wu & Frank J. Dann. (2009) Effects of tumor necrosis factor-α blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatologic Therapy 22:1, pages 61-73.
Crossref
Bruno Seriolo, Sabrina Paoliono, Carmela Ferrone & Maurizio Cutolo. (2009) Commentaires concernant l’article original de Soubrier et al. « Effets de la thérapie anti-TNF sur le profil lipidique chez des patients atteints de polyarthrite rhumatoïde ». Revue du Rhumatisme 76:1, pages 126-127.
Crossref
Bruno Seriolo, Sabrina Paoliono, Carmela Ferrone & Maurizio Cutolo. (2009) Comments on the original article by Soubrier et al. “Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis”. Joint Bone Spine 76:1, pages 117-118.
Crossref
Ricardo Blanco Alonso & Mario Agudo Bilbao. (2009) Inhibition of interleukin 6, a new therapeutic option in rheumatoid arthritis. Reumatología Clínica (English Edition) 5:3, pages 121-127.
Crossref
Adeline Ruyssen-Witrand, Gaël Mouterde, Emmanuelle Dernis, Philippe Gaudin, Daniel Wendling, Alain Cantagrel, Pascal Claudepierre, Bruno Fautrel, Jean-Francis Maillefert, Alain Saraux, Thierry Schaeverbeke, Jacques Tebib, Thao Pham & Xavier Le Loët. (2008) Tolérance des glucocorticoïdes dans la polyarthrite rhumatoïde : élaboration de recommandations pour la pratique clinique, à partir d’une analyse systématique de la littérature et de l’opinion d’experts. Revue du Rhumatisme 75, pages S20-S26.
Crossref
Sahena Haque, Hoda Mirjafari & Ian N Bruce. (2008) Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Current Opinion in Lipidology 19:4, pages 338-343.
Crossref
Saurabh S. Dhawan & Arshed A. Quyyumi. (2008) Rheumatoid arthritis and cardiovascular disease. Current Atherosclerosis Reports 10:2, pages 128-133.
Crossref
Josef S Smolen, Andre Beaulieu, Andrea Rubbert-Roth, Cesar Ramos-Remus, Josef Rovensky, Emma Alecock, Thasia Woodworth & Rieke Alten. (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. The Lancet 371:9617, pages 987-997.
Crossref
Martin Soubrier, Pierre Jouanel, Sylvain Mathieu, David Poujol, Delphine Claus, Jean-Jacques Dubost & Jean-Michel Ristori. (2008) Effets de la thérapie anti-TNF sur le profil lipidique chez des patients atteints de polyarthrite rhumatoïde. Revue du Rhumatisme 75:1, pages 25-27.
Crossref
Martin Soubrier, Pierre Jouanel, Sylvain Mathieu, David Poujol, Delphine Claus, Jean Jacques Dubost & Jean Michel Ristori. (2008) Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 75:1, pages 22-24.
Crossref
G. Stinco, F. Piccirillo & P. Patrone. (2007) Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis. British Journal of Dermatology 157:6, pages 1273-1274.
Crossref
W. Sterry, B.E. Strober & A. Menter. (2007) Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. British Journal of Dermatology 157:4, pages 649-655.
Crossref
Tohru Takeuchi, Toyofumi Nakanishi, Yoko Tabushi, Ayu Hata, Takeshi Shoda, Takuya Kotani, Akira Shimizu, Takayuki Takubo, Shigeki Makino & Toshiaki Hanafusa. (2007) Serum protein profile of rheumatoid arthritis treated with anti-TNF therapy (infliximab). Journal of Chromatography B 855:1, pages 66-70.
Crossref
Lai-Shan Tam, Brian Tomlinson, Tanya T. Chu, Tena K. Li & Edmund K. Li. (2007) Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clinical Rheumatology 26:9, pages 1495-1498.
Crossref
Kassie A. Haitz & Robert E. Kalb. (2007) Infliximab in the treatment of psoriasis in patients previously treated with etanercept. Journal of the American Academy of Dermatology 57:1, pages 120-125.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.